close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

4.880 -0.220 (-4.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Why Precision BioSciences Shares Are Surging Today ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Good morning! It's time to start off another busy day of trading with a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock ↗
 
Via Benzinga
News headline image
Precision BioSciences Highlights Interim Data From Allogeneic CAR T Programs In Blood Cancer Patients ↗
 
Via Benzinga
News headline image
Precision BioSciences: Q1 Earnings Insights ↗
Precision BioSciences (NASDAQ:DTIL) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
21 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Codex DNA, Inc. (NASDAQ: DNAY) rose 64.5% to $3.52 in pre-market trading after declining 10% on Tuesday. 
Via Benzinga
News headline image
US Stock Futures Down; Powell Testimony In Focus ↗
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones gained more than 600 points in the previous session. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Precision BioSciences Announces $50 Million Offering of Common Stock
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
From Precision BioSciences, Inc.
Via Business Wire
News headline image
69 Biggest Movers From Yesterday ↗
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 9.4% to $0.81 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million. 
Via Benzinga
News headline image
36 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) jumped 65% to $0.6382. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
From Precision BioSciences, Inc.
Via Business Wire
News headline image
69 Biggest Movers From Friday ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
News headline image
Precision BioSciences Earnings Perspective: Return On Capital Employed ↗
Benzinga Pro data, Precision BioSciences (NASDAQ:DTIL) reported Q1 sales of $3.32 million. Earnings fell to a loss of $28.17 million, resulting in a 26.37% decrease from last quarter. 
Via Benzinga
News headline image
Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Appoints Melinda Brown to Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Appoints Juli Blanche as Chief People Officer
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Preview: Precision BioSciences's Earnings ↗
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today